Strategic Partnerships TD2 Oncology is actively expanding through recent collaborations with Minerva Imaging and Panome Bio to broaden radiopharmaceutical development and integrated multi-omics capabilities, signaling outbound sales opportunities in imaging services, translational research, and combined omics-driven programs.

European Expansion With the 2024 European office expansion, TD2 is aiming to scale clinical trial services across Europe, presenting a cross-border CRO selling point for sponsors seeking European regulatory-ready preclinical and clinical support.

Clinical Excellence TD2 emphasizes precision preclinical and translational strategies rooted in omics research from its TGen heritage, creating upsell potential for sponsors requiring sophisticated biomarker-driven study design and early oncology asset characterization.

Leadership & Solutions New senior executives focused on strategic solutions and business operations suggest a push toward higher-touch, consultative selling, enabling TD2 to position as a strategic partner for portfolio optimization and risk mitigation in oncology programs.

Full-Service Growth Recent acquisition of Flow Contract Site Laboratory and broad service footprint across preclinical to clinical stages indicate capacity to consolidate vendor relationships, offering bundled services and integrated trials to mid-size biotechs seeking streamlined vendor management.